Science Business Announcements

The NIH has launched a phase 3 clinical trial to examine the use of prescription and over-the-counter medications for people with mild-to-moderate COVID-19. These individuals are not sick enough to be hospitalized. The trial is part of the Accelerating COVID 19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership. NIH will provide an initial investment of $155 million in funding for the trial, which will be overseen by the National Center for Advancing Translational Sciences.

The UC Davis MIND Institute is now offering online treatment appointments as part of its clinical trial known as the STAAR study. The trial will compare the effectiveness of the medication sertraline and cognitive behavioral therapy in treating anxiety in children with autism.

Computer gaming technology is being used to develop and pilot two low cost, next-generation screening tools for 'lazy eye' in children.

The strategic university partnership is aimed at embedding global and social responsibility into education and student experience.

A first participant was dosed at I-Motion, the pediatric clinical trial platform for neuromuscular diseases located at Trousseau hospital in Paris, as part of the gene therapy trial in Duchenne muscular dystrophy (DMD) conducted by Genethon.

Today, the International Osteoporosis Foundation (IOF) & Osteoporosis Canada (OC) announced the inclusion of 42 Fracture Liaison Services (FLS) from the Osteoporosis Canada FLS Registry on the Capture the Fracture® Map of Best Practice. The integration of the Canadian FLS on the Capture the Fracture® global map follows a collaboration agreement in which the two organizations underline their shared goal of improving clinical outcomes and preventing recurrent fractures in patients who have sustained fractures due to osteoporosis.

A hand surgeon at Hospital for Special Surgery performed the first surgery with an FDA-cleared total wrist replacement implant he designed.